Metabolic profiling of bile in cholangiocarcinoma using in vitro magnetic resonance spectroscopy

被引:47
作者
Sharif, Amar W. [1 ]
Williams, Horace R. T.
Lampejo, Temi
Khan, Shahid A.
Bansi, Devinder S.
Westaby, David
Thillainayagam, Andrew V.
Thomas, Howard C.
Cox, I. Jane [2 ]
Taylor-Robinson, Simon D.
机构
[1] Univ London Imperial Coll Sci Technol & Med, Liver Unit, Dept Med, Hepatol & Gastroenterol Sect, London W2 1NY, England
[2] Univ London Imperial Coll Sci Technol & Med, Imaging Sci Dept, MRC Clin Sci Ctr, Fac Med, London W2 1NY, England
关键词
bile acids; cholangiocarcinoma; metabonomic; magnetic resonance spectroscopy; phosphatidylcholine; PRIMARY SCLEROSING CHOLANGITIS; MORTALITY-RATES; P-GLYCOPROTEIN; ACIDS; DISEASE; DIAGNOSIS; CA-19-9; BILIARY; PROTON; CANCER;
D O I
10.1111/j.1477-2574.2010.00185.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives: Cholangiocarcinoma (CCA) has a poor prognosis and its aetiology is inadequately understood. Magnetic resonance spectroscopy (MRS) of bile may provide insights into the pathogenesis of CCA and help identify novel diagnostic biomarkers. The aim of this study was to compare the chemical composition of bile from patients with CCA with that of bile from patients with benign biliary disease. Methods: Magnetic resonance spectra were acquired from the bile of five CCA patients and compared with MRS of control bile from patients with benign biliary disease (seven with gallstones, eight with sphincter of Oddi dysfunction [SOD], five with primary sclerosing cholangitis [PSC]). Metabolic profiles were compared using both univariate and multivariate pattern-recognition analysis. Results: Univariate analysis showed that levels of glycine-conjugated bile acids were significantly increased in patients with CCA, compared with the benign disease groups (P = 0.002). 7 beta primary bile acids were significantly increased (P = 0.030) and biliary phosphatidylcholine (PtC) levels were reduced (P = 0.010) in bile from patients with CCA compared with bile from gallstone patients. These compounds were also of primary importance in the multivariate analysis: the cohorts were differentiated by partial least squares discriminant analysis (PLS-DA). Conclusions: These preliminary data suggest that altered bile acid and PtC metabolism play an important role in CCA aetiopathogenesis and that specific metabolites may have potential as future biomarkers.
引用
收藏
页码:396 / 402
页数:7
相关论文
共 30 条
  • [1] Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis
    Albiin, N.
    Smith, I. C. P.
    Arnelo, U.
    Lindberg, B.
    Bergquist, A.
    Dolenko, B.
    Bryksina, N.
    Bezabeh, T.
    [J]. ACTA RADIOLOGICA, 2008, 49 (08) : 855 - 862
  • [2] Bile acid feeding induces cholangiocyte proliferation and secretion: Evidence for bile acid-regulated ductal secretion
    Alpini, G
    Glaser, SS
    Ueno, Y
    Rodgers, R
    Phinizy, JL
    Francis, H
    Baiocchi, L
    Holcomb, LA
    Caligiuri, A
    LeSage, GD
    [J]. GASTROENTEROLOGY, 1999, 116 (01) : 179 - 186
  • [3] Bile acids as endogenous etiologic agents in gastrointestinal cancer
    Bernstein, Harris
    Bernstein, Carol
    Payne, Claire M.
    Dvorak, Katerina
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (27) : 3329 - 3340
  • [4] Detection and quantification of d-glucuronic acid in human bile using 1H NMR spectroscopy: relevance to the diagnosis of pancreatic cancer
    Bezabeh, Tedros
    Ijare, Omkar B.
    Albiin, Nils
    Arnelo, Urban
    Lindberg, Bo
    Smith, Ian C. P.
    [J]. MAGNETIC RESONANCE MATERIALS IN PHYSICS BIOLOGY AND MEDICINE, 2009, 22 (05) : 267 - 275
  • [5] CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis
    Björnsson, E
    Kilander, A
    Olsson, R
    [J]. LIVER, 1999, 19 (06): : 501 - 508
  • [6] Brindle JT, 2002, NAT MED, V8, P1439, DOI 10.1038/nm802
  • [7] Cox IJ, 2006, WORLD J GASTROENTERO, V12, P4773
  • [8] COX IJ, 1988, BRIT J HOSP MED, V40, P165
  • [9] Dixon RM, 1998, NMR BIOMED, V11, P370, DOI 10.1002/(SICI)1099-1492(1998110)11:7<370::AID-NBM514>3.0.CO
  • [10] 2-#